Ares Allergy Holding PLC (STAGR)

Stallergenes Greer Ltd engages in the development and commercialization of allergy immunotherapy products and services for diagnosis and treatment of allergies. The company offers sublingual products consisting of Staloral, an oral drop for the treatment of allergy involving rhinitis, conjunctivitis, rhinoconjunctivitis, and asthma; Actair and Orylmyte for the treatment of house dust mite; and Oralair for grass pollen allergic patients. It also provides subcutaneous products, such as Alustal for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and mild to moderate asthma in adults and children; and Albey venom for the treatment of allergy to wasp, honeybee, and yellow jacket venom. In addition, the company offers GREER Extracts for subcutaneous and sublingual administration; GREER Sterile Diluents that offers a range of various sizes, formulations, and fill volumes; GREER Sterile Empty Vials, which comprises a range of industry-relevant sizes for extract mixing and storage for veterinary applications. Further, it provides testing devices. The company has a partnership with Aptar Pharma to develop a connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions. It enters a research collaboration with Imperial College London. The company was formerly known as Ares Allergy Holdings plc and changed its name to Stallergenes Greer Ltd in May 2019. Stallergenes Greer Ltd was incorporated in 2013 and is based in London, United Kingdom.